{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T04:18:11Z","timestamp":1774153091659,"version":"3.50.1"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Risk-targeted testing and treatment of latent tuberculosis infection (LTBI) is a critical component of the United States\u2019 (US) tuberculosis (TB) elimination strategy, but relatively low treatment completion rates remain a challenge. Both treatment persistence and completion may be facilitated by diagnosing LTBI using interferon gamma release assays (IGRA) rather than tuberculin skin tests (TST).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We used a national sample of administrative claims data to explore associations diagnostic test choice (TST, IGRA, TST with subsequent IGRA) and treatment persistence and completion in persons initiating a daily dose isoniazid LTBI treatment regimen in the US private healthcare sector between July 2011 and March 2014. Associations were analyzed with a generalized ordered logit model (completion) and a negative binomial regression model (persistence).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of 662 persons initiating treatment, 327 (49.4%) completed at least the 6-month regimen and 173 (26.1%) completed the 9-month regimen; 129 (19.5%) persisted in treatment one month or less. Six-month completion was least likely in persons receiving a TST (42.2%) relative to persons receiving an IGRA (55.0%) or TST then IGRA (67.2%; p = 0.001). Those receiving an IGRA or a TST followed by an IGRA had higher odds of completion compared to those receiving a TST (aOR = 1.59 and 2.50; p = 0.017 and 0.001, respectively). Receiving an IGRA or a TST and subsequent IGRA was associated with increased treatment persistence relative to TST (aIRR = 1.14 and 1.25; p = 0.027 and 0.009, respectively).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>IGRA use is significantly associated with both higher levels of LTBI treatment completion and treatment persistence. These differences are apparent both when IGRAs alone were administered and when IGRAs were administered subsequent to a TST. Our results suggest that IGRAs contribute to more effective LTBI treatment and consequently individual and population protections against TB.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0243102","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T19:03:41Z","timestamp":1607022221000},"page":"e0243102","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-6722","authenticated-orcid":true,"given":"Erica L.","family":"Stockbridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiah D.","family":"Loethen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Annan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"issue":"11","key":"pone.0243102.ref001","first-page":"286","article-title":"Tuberculosis\u2014United States, 2019","volume":"69","author":"NG Schwartz","year":"2020","journal-title":"MMWR"},{"issue":"9","key":"pone.0243102.ref002","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/aje\/kwy094","article-title":"Prospects for tuberculosis elimination in the United States: results of a transmission dynamic model","volume":"187","author":"NA Menzies","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"10","key":"pone.0243102.ref003","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1017\/S095026881100286X","article-title":"Modelling tuberculosis trends in the USA","volume":"140","author":"AN Hill","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"2","key":"pone.0243102.ref004","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup","volume":"179","author":"KM Shea","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pone.0243102.ref005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"P Lobue","year":"2010","journal-title":"Respirology"},{"issue":"11","key":"pone.0243102.ref006","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"H Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0243102.ref007","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12879-016-1550-y","article-title":"Initiation and completion rates for latent tuberculosis infection treatment: a systematic review","volume":"16","author":"AA Sandgren","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"11","key":"pone.0243102.ref008","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Y Hirsch-Moverman","year":"2008","journal-title":"The Int J Tuberc Lung Dis"},{"issue":"4","key":"pone.0243102.ref009","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1097\/PHH.0000000000000628","article-title":"Tuberculosis prevention in the private sector: using claims-based methods to identify and evaluate latent tuberculosis infection treatment with isoniazid among the commercially insured","volume":"24","author":"EL Stockbridge","year":"2017","journal-title":"J Public Health Manag Pract"},{"issue":"4","key":"pone.0243102.ref010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3122\/jabfm.2017.04.170070","article-title":"Factors that influence treatment completion for latent tuberculosis infection","volume":"30","author":"MC Eastment","year":"2017","journal-title":"J Am Board Fam Med"},{"issue":"1","key":"pone.0243102.ref011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: A retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"AH McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0243102.ref012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5588\/ijtld.14.0373","article-title":"Latent tuberculous infection in the United States and Canada: who completes treatment and why?","volume":"19","author":"Y Hirsch-Moverman","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"pone.0243102.ref013","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","article-title":"Improved treatment completion with shorter treatment regimens for latent tuberculous infection","volume":"22","author":"MM Macaraig","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"pone.0243102.ref014","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5588\/ijtld.16.0617","article-title":"Tuberculosis skin test and interferon gamma release assays usage among privately insured persons in the US","volume":"21","author":"K Owusu-Edusei","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"pone.0243102.ref015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw694","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"DM Lewinsohn","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pone.0243102.ref016","unstructured":"Centers for Disease Control and Prevention. Tuberculosis (tb): Testing in BCG-vaccinated persons 2016 [updated April 15, 2016; cited 2020 July 21]. Available from: https:\/\/www.cdc.gov\/tb\/topic\/testing\/testingbcgvaccinated.htm."},{"key":"pone.0243102.ref017","unstructured":"World Health Organization. Global health observatory data repository: BCG immunization coverage estimates by country 2018 [cited 2020 July 21]. Available from: https:\/\/apps.who.int\/gho\/data\/node.main.A830?lang=en."},{"issue":"11","key":"pone.0243102.ref018","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011\u20132012","volume":"10","author":"R Miramontes","year":"2015","journal-title":"PloS one"},{"issue":"4","key":"pone.0243102.ref019","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201508-1683OC","article-title":"The prevalence of latent tuberculosis infection in the United States","volume":"194","author":"JD Mancuso","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0243102.ref020","doi-asserted-by":"crossref","first-page":"1178636118811311","DOI":"10.1177\/1178636118811311","article-title":"Impact of choice of test for latent tuberculosis infection on treatment acceptance and completion","volume":"11","author":"LA Lambert","year":"2018","journal-title":"Microbiol insights"},{"issue":"9","key":"pone.0243102.ref021","doi-asserted-by":"crossref","first-page":"e0138349","DOI":"10.1371\/journal.pone.0138349","article-title":"Enhanced tuberculosis infection treatment outcomes after implementation of Quantiferon\u00ae-Gold testing","volume":"10","author":"A Crossa","year":"2015","journal-title":"PLoS One"},{"key":"pone.0243102.ref022","doi-asserted-by":"crossref","first-page":"h705","DOI":"10.1136\/bmj.h705","article-title":"Too much technology","volume":"350","author":"BM Hofmann","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"pone.0243102.ref023","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1399-5618.2007.00434.x","article-title":"Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients' beliefs about the condition and its treatment","volume":"9","author":"J Clatworthy","year":"2007","journal-title":"Bipolar disord"},{"issue":"5","key":"pone.0243102.ref024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jpsychores.2004.11.010","article-title":"Secondary prevention of coronary heart disease: patient beliefs and health-related behaviour","volume":"58","author":"M Byrne","year":"2005","journal-title":"J Psychosom Res"},{"issue":"1","key":"pone.0243102.ref025","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-5578-3","article-title":"Predictors of latent tuberculosis infection treatment completion in the US private sector: an analysis of administrative claims data","volume":"18","author":"EL Stockbridge","year":"2018","journal-title":"BMC Public Health"},{"issue":"5","key":"pone.0243102.ref026","doi-asserted-by":"crossref","first-page":"e36551","DOI":"10.1371\/journal.pone.0036551","article-title":"Programmatic impact of Quantiferon-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic","volume":"7","author":"M Shah","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"pone.0243102.ref027","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2105\/AJPH.2019.305069","article-title":"Quantiferon-TB Gold versus tuberculin screening and care retention among persons experiencing homelessness: Georgia, 2015\u20132017","volume":"109","author":"JM Collins","year":"2019","journal-title":"Am J Public Health"},{"issue":"12","key":"pone.0243102.ref028","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.5588\/ijtld.11.0102","article-title":"Programmatic impact of using Quantiferon-TB Gold in routine contact investigation activities","volume":"15","author":"JA Grinsdale","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"pone.0243102.ref029","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"GW Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"pone.0243102.ref030","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1473-3099(17)30248-7","article-title":"Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA","volume":"17","author":"PA LoBue","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pone.0243102.ref031","author":"Institute of Medicine Committee on the Elimination of Tuberculosis in the United States","year":"2000"},{"key":"pone.0243102.ref032","unstructured":"Optum. Clinformatics data mart 2014 [cited 2020 July 21]. Available from: https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf."},{"issue":"2","key":"pone.0243102.ref033","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"CR Horsburgh","year":"2010","journal-title":"Chest"},{"issue":"1","key":"pone.0243102.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"TR Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"pone.0243102.ref035","unstructured":"Centers for Disease Control and Prevention. Treatment regimens for latent tb infection (LTBI). 2016 [updated February 13, 2020; cited 2020 July 21]. Available from: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/ltbi.htm."},{"key":"pone.0243102.ref036","unstructured":"Centers for Disease Control and Prevention. Nchs urban-rural classification scheme for counties. 2014 [updated May 6, 2014; cited 2020 July 21]. Available from: http:\/\/www.cdc.gov\/nchs\/data_access\/urban_rural.htm."},{"key":"pone.0243102.ref037","unstructured":"Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2012. 2013 [cited 2020 July 21]. Available from: https:\/\/www.cdc.gov\/tb\/statistics\/reports\/2012\/default.htm."},{"key":"pone.0243102.ref038","unstructured":"United States Census Bureau. American community survey (ACS) 2015 [cited 2020 July 21]. Available from: https:\/\/www.census.gov\/programs-surveys\/acs\/."},{"issue":"RR-6","key":"pone.0243102.ref039","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR"},{"issue":"1","key":"pone.0243102.ref040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/1536867X0600600104","article-title":"Generalized ordered logit\/partial proportional odds models for ordinal dependent variables","volume":"6","author":"R Williams","year":"2006","journal-title":"Stata J"},{"key":"pone.0243102.ref041","doi-asserted-by":"crossref","first-page":"381929","DOI":"10.1155\/2012\/381929","article-title":"Immunosuppression adversely affects TST but not IGRAs in patients with psoriasis or inflammatory musculoskeletal diseases","volume":"2012","author":"E Tavast","year":"2012","journal-title":"Int J Rheumatol"},{"issue":"10","key":"pone.0243102.ref042","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/ajt.13330","article-title":"Superior sensitivity of ex vivo ifn-\u03b3 release assays as compared to skin testing in immunocompromised patients","volume":"15","author":"T Scholman","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"pone.0243102.ref043","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/003335491513000413","article-title":"Tuberculosis elimination efforts in the United States in the era of insurance expansion and the Affordable Care Act","volume":"130","author":"V Balaban","year":"2015","journal-title":"Public Health Rep"},{"issue":"9","key":"pone.0243102.ref044","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2016.11046","article-title":"Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement","volume":"316","author":"US Preventive Services Task Force","year":"2016","journal-title":"JAMA"},{"key":"pone.0243102.ref045","unstructured":"Government Publishing Office. Patient protection and affordable care act: Section 6301 2010 [cited 2020 July 21]. Available from: http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-111publ148\/pdf\/PLAW-111publ148.pdf."},{"key":"pone.0243102.ref046","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12879-016-1549-4","article-title":"Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review","volume":"16","author":"AL Stuurman","year":"2016","journal-title":"BMC Infect. Dis"},{"issue":"4","key":"pone.0243102.ref047","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.ijid.2009.05.007","article-title":"Adherence to treatment of latent tuberculosis infection in a clinical population in New York City","volume":"14","author":"JJ Li","year":"2010","journal-title":"Int J Infecti Dis"},{"issue":"3","key":"pone.0243102.ref048","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jinf.2006.04.010","article-title":"Predictors of failure to complete treatment for latent tuberculosis infection","volume":"54","author":"AE Parsyan","year":"2007","journal-title":"Journal Infecti"},{"issue":"4","key":"pone.0243102.ref049","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.eurpsy.2009.07.012","article-title":"Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database","volume":"25","author":"MC Serna","year":"2010","journal-title":"Eur Psychiatry"},{"issue":"3","key":"pone.0243102.ref050","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12325-013-0016-5","article-title":"Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia","volume":"30","author":"S Offord","year":"2013","journal-title":"Adv Ther"},{"issue":"5","key":"pone.0243102.ref051","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cjca.2012.03.018","article-title":"Nonadherence to statin therapy: Discontinuation after a single fill","volume":"28","author":"M Lemstra","year":"2012","journal-title":"The Can J Cardiol"},{"key":"pone.0243102.ref052","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CEOR.S117200","article-title":"Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US","volume":"9","author":"J Lin","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"pone.0243102.ref053","first-page":"207","article-title":"Factors contributing to compliance with osteoporosis medication","volume":"10","author":"J Kertes","year":"2008","journal-title":"Isr Med Assoc J"},{"issue":"5","key":"pone.0243102.ref054","first-page":"483","article-title":"Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications","volume":"23","author":"D Swieczkowski","year":"2016","journal-title":"Cardiol J"},{"issue":"11","key":"pone.0243102.ref055","first-page":"CD000011","article-title":"Interventions for enhancing medication adherence","volume":"2014","author":"R Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pone.0243102.ref056","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5588\/ijtld.19.0185","article-title":"Interventions to reduce losses in the cascade of care for latent tuberculosis: a systematic review and meta-analysis","volume":"24","author":"L Barss","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0243102.ref057","unstructured":"Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers 2020 [cited 2020 July 21]. Available from: https:\/\/www.cdc.gov\/tb\/publications\/ltbi\/."},{"issue":"1","key":"pone.0243102.ref058","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.publhealth.22.1.213","article-title":"Administrative data for public health surveillance and planning","volume":"22","author":"BAB Virnig","year":"2001","journal-title":"Annu Rev Public Health"},{"issue":"4","key":"pone.0243102.ref059","doi-asserted-by":"crossref","DOI":"10.5588\/ijtld.16.0587","article-title":"Tuberculosis hospitalization expenditures per patient from private health insurance claims data, 2010\u20132014","volume":"21","author":"K Owusu-Edusei","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"pone.0243102.ref060","doi-asserted-by":"crossref","first-page":"e0193432","DOI":"10.1371\/journal.pone.0193432","article-title":"Private sector tuberculosis prevention in the US: characteristics associated with interferon-gamma release assay or tuberculin skin testing","volume":"13","author":"EL Stockbridge","year":"2018","journal-title":"PLoS One"},{"key":"pone.0243102.ref061","article-title":"Factors associated with latent tuberculosis infection treatment failure among patients with commercial health insurance-United States, 2005\u20132016","author":"SA Iqbal","year":"2019","journal-title":"J Public Health Manag Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T19:05:04Z","timestamp":1607022304000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243102"}},"subtitle":[],"editor":[{"given":"Frederick","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243102","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}